Welcome to Erlend B. Smeland's group:
Lymphomas & Lymphocyte biology

The main focus of our research is to study B-cell lymphoma biology, and we perform molecular characterization as well as functional studies. Lymphomas are cancers derived from the cells of the immune system, and most often they arise from B-cells in the lymph nodes. By the means of high throughput analysis of gene expression and genomic and epigenetic alterations in lymphoma samples, we aim to elucidate oncogenetic mechanisms in lymphoma development. We also aim to identify prognostic markers and characterize biologically different subgroups of lymphoma.
We have a strong translational focus with a close collaboration with the lymphoma program in the Hospital and an extensive international collaboration. Several projects are connected to ongoing clinical trials, and we analyze primary patient samples using a broad spectrum of methods.
Selected lymphoma-specific genetic aberrations are followed up by basic cell biology research, using B cell lymphoma cell lines as models. Central techniques include studies of signalling pathways by Western blot analysis and multicolour flow cytometry, confocal microscopy, tissue micro array (TMA), array copy number genetic changes (aCGH), and gene expression profiling.
An overview of our key achievements can be found here.
The group is a member of Center for Cancer Biomedicine.
Molecular characterisation and studies of gene expression.
Epigenetic mechanisms in the development of malignant lymphoma
TGF-beta/BMP-induced signaling and functional effects in normal and malignant B-cells
High-throughput profiling of signaling pathways in B-cell lymphoma by Phospho-Flow cytometry
Lymphoma/Leukemia Molecular Profiling Project (LLMPP)
Contact information:
Department of Immunology, Institute for Cancer Research
The Norwegian Radium Hospital
Montebello
0310 Oslo, Norway
| Phone: | +47 22 78 14 17 (Smeland) |
| +47 22 78 12 66 (Secretary) | |
| +47 22 93 40 00 (switchboard) | |
| Fax: | +47 22 78 13 45 |
Email to E. Smeland: ebs@rr-research.no
Jun 14, 2013
International approaches to personalized cancer medicine
Jun 5, 2013
Latest publications
Erlend B. Smeland's group
Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy
Leuk Lymphoma (in press)
PubMed 23662992
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation
BMC Genomics, 13, 591
PubMed 23442169
Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
Leuk Lymphoma (in press)
PubMed 23391141




Print this page
